Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 15th total of 5,060,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is currently 2.6 days.
Adaptimmune Therapeutics Stock Down 1.7 %
ADAP stock opened at $0.58 on Tuesday. The company’s 50 day moving average price is $0.63 and its 200 day moving average price is $0.90. The firm has a market capitalization of $148.39 million, a price-to-earnings ratio of -2.64 and a beta of 2.24. Adaptimmune Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $2.05. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. HC Wainwright decreased their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Mizuho reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. Guggenheim dropped their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, StockNews.com lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $2.79.
Institutional Investors Weigh In On Adaptimmune Therapeutics
Several institutional investors have recently modified their holdings of the company. Virtu Financial LLC raised its holdings in Adaptimmune Therapeutics by 27.5% during the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 21,769 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 30,000 shares during the last quarter. Fullcircle Wealth LLC purchased a new stake in Adaptimmune Therapeutics in the third quarter valued at $33,000. FMR LLC boosted its stake in Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after acquiring an additional 50,419 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 98,581 shares in the last quarter. 31.37% of the stock is owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Read More
- Five stocks we like better than Adaptimmune Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Airline Stocks – Top Airline Stocks to Buy Now
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.